NASDAQ$MIST
Milestone Pharmaceuticals Inc · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported financial results for the first quarter ended March 31, 2024 and provided a regulatory and corporate update.
Milestone Pharmaceuticals reported their Q1 2024 financial results and provided a regulatory and corporate update, highlighting the NDA resubmission for etripamil in PSVT and sufficient cash resources to fund operations into 2026.
- NDA for etripamil in PSVT was resubmitted in Q1 2024.
- Cash resources as of March 31, 2024 are expected to fund operations into 2026.
- Dialogue with FDA to finalize Phase 3 protocol for etripamil in AFib-RVR is progressing.
- The company anticipates potential FDA approval of CARDAMYST™ (etripamil) nasal spray in the first half of 2025.
Headline financials
Revenue & EPS history
Milestone Pharmaceuticals · Revenue · Quarterly
$0
Forward guidance
Milestone Pharmaceuticals is on track for potential FDA approval of CARDAMYST™ (etripamil) nasal spray in the first half of 2025 and expects current cash position, together with a potential future synthetic royalty payment, provides the needed resources to launch CARDAMYST in the U.S. market for patients suffering from PSVT.
Tailwinds
- Potential FDA approval of CARDAMYST™ (etripamil) nasal spray in the first half of 2025.
- Current cash position, together with a potential future synthetic royalty payment, provides the needed resources to launch CARDAMYST in the U.S. market for patients suffering from PSVT.
- The company remains focused on working with FDA through the review process.
- The company is preparing for commercialization and launch readiness.
- Etripamil is designed as a self-administered rapid response therapy for patients thereby bypassing the need for immediate medical oversight.
Headwinds
- The timing and outcomes of future interactions with U.S. and foreign regulatory bodies, including the FDA, including the timing of the FDA’s review of the NDA are uncertain.
- The timing of the receipt of the future synthetic royalty payment is uncertain.
- There are risks inherent in biopharmaceutical product development and clinical trials, including the lengthy and uncertain regulatory approval process.
- Uncertainties related to the timing of initiation, enrollment, completion, evaluation and results of clinical trials.
- General economic, political, and market conditions, including deteriorating market conditions due to investor concerns regarding inflation, Russian hostilities in Ukraine and ongoing disputes in Israel and Gaza and overall fluctuations in the financial markets in the United States and abroad.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q1 2024
+2.5%
Avg return
Earnings day
+0.9%
Avg return
5 days after
+1.5%
Avg return
30 days after
67%
18 / 27 earnings
Positive
+24.1%
Q3 2021
Best reaction
-23.0%
Q3 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | — | — | — | |
| Q1 2026 | -9.5% | -23.2% | — | |
| Q3 2025 | +1.0% | +21.5% | +26.2% | |
| Q2 2025 | +7.1% | +9.7% | +23.2% | |
| Q1 2025 | -1.7% | +8.4% | +38.7% | |
| Q4 2024 | +7.9% | -53.7% | -38.9% | |
| Q3 2024 | -5.2% | -12.4% | -4.1% | |
| Q1 2024 | +1.2% | +2.4% | -16.5% | |
| Q4 2023 | +16.0% | +20.7% | +9.3% | |
| Q3 2023 | -23.0% | -24.4% | -13.7% | |
| Q2 2023 | +1.6% | +2.6% | -7.1% | |
| Q1 2023 | +12.8% | +0.5% | +1.3% | |
| Q4 2022 | -4.0% | -0.3% | -9.0% | |
| Q3 2022 | +13.0% | +7.1% | -0.7% | |
| Q2 2022 | +3.6% | +5.3% | +29.2% | |
| Q1 2022 | -2.5% | +1.6% | +1.6% | |
| Q4 2021 | +12.4% | +17.5% | +22.0% | |
| Q3 2021 | +24.1% | +13.9% | +4.5% | |
| Q2 2021 | +0.2% | +2.1% | +7.1% | |
| Q1 2021 | +0.5% | +2.9% | +8.1% | |
| Q4 2020 | -6.6% | -2.4% | -4.2% | |
| Q3 2020 | +6.1% | +6.0% | +19.8% | |
| Q2 2020 | -1.8% | +0.3% | -12.2% | |
| Q1 2020 | +0.3% | +4.8% | +29.5% | |
| Q4 2019 | +7.4% | +8.7% | -90.4% | |
| Q3 2019 | -4.2% | -1.2% | -7.2% | |
| Q2 2019 | +7.8% | +9.9% | +38.1% | |
| Q1 2019 | +3.4% | -4.5% | -16.2% | |
| Q4 2018 | — | — | — | |
| Q3 2018 | — | — | — | |
| Q2 2018 | — | — | — | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro